Skip to main content
Top
Published in: Intensive Care Medicine 7/2004

01-07-2004 | Correspondence

Author’s reply to the comments by de Rooij and de Jonge

Authors: Nicolas Bergeron, Yoanna Skrobik

Published in: Intensive Care Medicine | Issue 7/2004

Login to get access

Excerpt

Sir: We thank Drs. Sophia de Rooij and Evert de Jonge for emphasizing the importance that delirium has on the critically ill patient’s outcome. Removing offending agents, treating suspected causal medical conditions, and reducing the impact of environmental factors are the recommended, if not evidence-based, first steps to managing ICU delirium [1]. Associated psychiatric symptoms and/or behavioral disturbances often require pharmacological intervention [1]. Haloperidol, especially the intravenous form, has been proposed as the treatment of choice for the symptomatic management of delirium in the intensive care setting [2, 3]. However, the use of intravenous haloperidol in ICU delirium is based primarily on historical rather than scientific grounds; this indication is not approved by the United States Food and Drug Administration. …
Literature
1.
go back to reference American Psychiatric Association (1999) Practice guideline for the treatment of patients with delirium. Am J Psychiatry 156:1–20 American Psychiatric Association (1999) Practice guideline for the treatment of patients with delirium. Am J Psychiatry 156:1–20
2.
go back to reference Wise MG, Cassem NH (1998) Behavioural disturbances in the ICU. In: Civetta JM, Taylor RW, Kirby RR (eds) Critical care. Lippincott, Philadelphia, pp 1595–1604 Wise MG, Cassem NH (1998) Behavioural disturbances in the ICU. In: Civetta JM, Taylor RW, Kirby RR (eds) Critical care. Lippincott, Philadelphia, pp 1595–1604
3.
go back to reference Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke S, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA, Murray MJ, Peruzzi WT, Lumb PD (2002) Clinical Practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 30:119–141PubMed Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke S, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA, Murray MJ, Peruzzi WT, Lumb PD (2002) Clinical Practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 30:119–141PubMed
4.
go back to reference Skrobik Y, Bergeron N, Dumont M, Gottfried SB (2004) Olanzapine vs. haloperidol in a critical care setting. Intensive Care Med 30:440–444CrossRef Skrobik Y, Bergeron N, Dumont M, Gottfried SB (2004) Olanzapine vs. haloperidol in a critical care setting. Intensive Care Med 30:440–444CrossRef
5.
go back to reference Wooltorton E, Risperidone (2002) increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 167:1269–1270 Wooltorton E, Risperidone (2002) increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 167:1269–1270
6.
go back to reference Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y (2001) Delirium in an intensive care unit: a study of risk factors. Intensive Care Med 27:1297–1304CrossRef Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y (2001) Delirium in an intensive care unit: a study of risk factors. Intensive Care Med 27:1297–1304CrossRef
Metadata
Title
Author’s reply to the comments by de Rooij and de Jonge
Authors
Nicolas Bergeron
Yoanna Skrobik
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 7/2004
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-004-2330-5

Other articles of this Issue 7/2004

Intensive Care Medicine 7/2004 Go to the issue